APELLIS PHARMACEUTICALS, INC. Item 8.01 Other Events
On
In a pre-specified analysis of GA lesion growth over 24 months, both monthly and every-other-month ("EOM") pegcetacoplan showed a clinically meaningful reduction in GA lesion growth from baseline compared to sham (all p-values are nominal):
• DERBY: 19% monthly, p=0.0004; 16% EOM, p=0.0030 • OAKS: 22% monthly, p<0.0001; 18% EOM, p=0.0002
Between months 18-24, the pegcetacoplan treatment effect accelerated compared to previous six-month periods, with robust reductions of GA lesion growth versus sham (all p-values are nominal). The increased effects were driven by a greater slowing of lesion growth by pegcetacoplan and not by an increase in the lesion growth rate in the sham group, which was highly consistent over each of the four six-month intervals (1.0+/-0.05 mm2).
• DERBY: 36% monthly, p<0.0001; 29% EOM, p=0.0002 • OAKS: 24% monthly, p=0.0080; 25% EOM, p=0.0007
Additionally, the reduction of GA lesion growth in patients with extrafoveal lesions (28% monthly; 28% EOM) was comparable to the reduction in patients with foveal lesions (34% monthly; 28% EOM) in the combined studies between months 18-24.
During the six-month period between months 18-24, the treatment effect of pegcetacoplan in the pooled data increased compared to previous six-month periods, with reductions of GA lesion growth of 30% and 24% in the monthly and every-other-month arms, respectively, with nominal p-values < 0.0001 in both arms, when compared against pooled sham. Due to the statistical model used to analyze combined patient-level data, the treatment effect in the pooled data is not a simple average of the DERBY and OAKS results.
The nominal p-values presented above were calculated using the same methodologies as the month 12 and 18 analyses.
Consistent with expectations, no clinically meaningful difference was observed between pegcetacoplan and sham in the key secondary outcomes measuring visual function at 24 months. Studies show that GA lesion growth is correlated with loss of visual function over longer periods of time. The visual function outcomes at 24 months are believed to be due to the limitations of the endpoints when used for GA and the relatively early assessment timeframe. Patients will be treated with pegcetacoplan in the GALE open label extension study for an additional three years. All patients who completed the DERBY or OAKS studies were invited to participate in the GALE study. The objective of the GALE study is to evaluate the long-term incidence and severity of ocular and system treatment emergent adverse events as well as change in the total area of GA lesions as measured by fundus autofluorescence.
Pegcetacoplan continued to demonstrate a favorable safety profile, consistent with safety data to date and longer-term exposure to intravitreal injections. No cases of endophthalmitis were reported between months 18 and 24. Over 24 months, the rate of infectious endophthalmitis was 0.034% per injection and the rate of intraocular inflammation was 0.24% per injection, which continue to be generally in line with reported rates in studies of other intravitreal therapies. No events of occlusive vasculitis or retinitis were observed over 24 months, and no serious adverse events of ischemic optic neuropathy were reported between months 18 and 24. The combined rate of new-onset exudations at month 24 was 11.9%, 6.7%, and 3.1% in the pegcetacoplan monthly, every-other-month, and sham groups, respectively.
--------------------------------------------------------------------------------
The results at 24 months will be included in the marketing authorization
application that the Company plans to submit to the
The Company expects to present detailed data at upcoming medical congresses.
Forward-Looking Statements
Statements in this Current Report on Form 8-K about future expectations, plans
and prospects, as well as any other statements regarding matters that are not
historical facts, may constitute "forward-looking statements" within the meaning
of The Private Securities Litigation Reform Act of 1995. These statements
include, but are not limited to, statements regarding timing of anticipated
regulatory submissions. The words "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential," "predict,"
"project," "should," "target," "will," "would" and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Actual results may
differ materially from those indicated by such forward-looking statements as a
result of various important factors, including whether the results of the FILLY,
DERBY and OAKS trials are sufficient to support regulatory submissions; whether
a submission for approval of intravitreal pegcetacoplan for GA on the basis of
the FILLY, DERBY and OAKS trials will be accepted by the
--------------------------------------------------------------------------------
© Edgar Online, source
